← FDA DRUG APPROVALS

FDA ANDA · ANDA064093

GENTAMICIN SULFATE

Sponsor: SCIEGEN PHARMS

APPLICATION
ANDA064093
TYPE
ANDA
ORIGINAL APPROVAL
1995-08-31
LATEST ACTION
2017-03-10
ROUTE
OPHTHALMIC
DOSAGE FORM
OINTMENT
MARKETING STATUS
Discontinued

Products

GENTAMICIN SULFATEDiscontinued
GENTAMICIN SULFATE EQ 0.3% BASE · OINTMENT · OPHTHALMIC

Approval history

2017-03-10Manufacturing (CMC) · Supplement 11 · unknownAP
1999-04-27Manufacturing (CMC) · Supplement 3AP
1996-06-24Manufacturing (CMC) · Supplement 2AP
1995-12-28Manufacturing (CMC) · Supplement 1AP
1995-08-31OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →